ClinicalTrials.gg
TerminatedNCT04472494Updated Oct 7, 2022Results posted

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

A Phase 2 interventional study of Abatacept and Placebo in COVID-19 and SARS-CoV-2, sponsored by Bristol-Myers Squibb. Terminated at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-07.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was terminated
Slow accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
744th of 1,321
61 · median 91
Started
2020
with 817 others
Phase 2
349 of 1,859
14 open now
Registered
525th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 744th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 525th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.

03

Conditions studied

  • COVID-19
  • SARS-CoV-2

Keywords

  • Coronavirus disease 2019 (COVID-19)
  • Coronavirus
  • Coronavirus infections
  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A confirmed virological diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (by reverse-transcription polymerase chain reaction (RT-PCR)).
  • Hospitalized (or in the Emergency Department awaiting a bed after hospitalization)
  • Respiratory compromise as defined by requirement of oxygen supplementation to maintain oxygen saturation ≥ 93% but not requiring mechanical ventilation
  • Abnormal chest X-ray consistent with COVID-19 and not indicating other serious medical condition that would serve as an exclusionary criteria
  • Women and men must agree to follow specific methods of , if applicable

Exclusion criteria

Exclusion Criteria:

  • Women who are breastfeeding
  • Recent acute infection defined as:

    i) Any acute infection within 60 days prior to randomization that required hospitalization or treatment with parenteral antibiotics (not COVID-19 related) ii) Any acute infection within 30 days prior to randomization that required oral antimicrobial or antiviral therapy

  • History of chronic or recurrent bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, bronchiectasis)
  • Prior exposure to BMS-188667 (abatacept)

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Abatacept + Standard of care

    Biological: Abatacept

  • Placebo comparator
    Placebo infusion + Standard of care

    Other: Placebo

Interventions

  • BiologicalAbatacept

    Specified dose on specified days

    Also known as: ORENCIA®, BMS-188667

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Percentage of Participants on Invasive Mechanical Ventilation or Died Prior to or on Day 28

    The percentage of participants on invasive mechanical ventilation is defined as the delivery of positive pressure to the lungs via an endotracheal tube (or tracheostomy) or death prior to or on day 28.

    Time frame: From first dose to 28 days post first dose

Secondary outcomes

  1. Adjusted Mean Change From Baseline in the Ordinal 8-Point Clinical Status Scale on Day 28

    Adjusted mean change from baseline based on the following Ordinal 8-point Clinical Status Scale that was proposed for the National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trial (ACTT) and is recorded by the worst score (lowest number) state for each day: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, on non-invasive mechanical ventilation or high-flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized, limitation on activities and/or requiring home oxygen; 8. Not hospitalized, no limitation on activities Baseline is defined as the last assessment done prior or on Day 1

    Time frame: Baseline and on Day 28

  2. Percentage of Participants Who Died

    Percentage of participants who died due to any cause. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 1) Death

    Time frame: From first dose to 28 days post first dose

  3. Percentage of Participants Alive and Free of Respiratory Failure on Day 28±3

    Respiratory failure is defined by the type of resources required as defined by the use of any of these: Mechanical ventilation, extracorporeal membrane oxygenation (ECMO) or oxygen delivery by noninvasive positive pressure or high flow nasal cannula. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitation on activities

    Time frame: Day 28±3

  4. Percentage of Participants Returned to Room Air on Day 28

    Recovery of pulmonary function is assessed by the percentage of participants returned to room air on day 28 after they were oxygen dependent and dependence on oxygen has been noted to be prolonged even after hospital discharge. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 8) Not hospitalized, no limitation on activities

    Time frame: Day 28

  5. Percentage of Participants Alive and Discharged From the Hospital by Day 28

    Percentage of participants alive and discharged from the hospital on day 28. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitation on activities

    Time frame: From day 1 up to day 28

  6. Percentage of Participants With Serious Adverse Events

    Percentage of participants with serious adverse events (SAEs). SAE is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life threatening * Requires inpatient hospitalization * Results in persistent or significant disability * Is a congenital anomaly/birth defect * Is an important medical event

    Time frame: From first dose to 60 days post first dose

  7. Percentage of Participants With Serious Adverse Events (SAEs) of the Infections and Infestations System Organ Class

    Percentage of participants with Serious Adverse Events (SAEs) of the infections and infestations System Organ Class (SOC)

    Time frame: From first dose to 60 days post first dose

07

Results

Posted Oct 7, 2022

Participant flow

Pre-treatment
Participant flow — Pre-treatment
MilestoneAbataceptPlacebo
Started4219
Completed4019
Not completed20
Withdrew: Other reasons20
Treatment
Participant flow — Treatment
MilestoneAbataceptPlacebo
Started4019
Completed3416
Not completed63
Withdrew: Death52
Withdrew: Hospital discharge11

Outcome measures

PrimaryPercentage of Participants on Invasive Mechanical Ventilation or Died Prior to or on Day 28

The percentage of participants on invasive mechanical ventilation is defined as the delivery of positive pressure to the lungs via an endotracheal tube (or tracheostomy) or death prior to or on day 28.

Time frame:
From first dose to 28 days post first dose
Reported as:
Number · Percentage of participants
Percentage of Participants on Invasive Mechanical Ventilation or Died Prior to or on Day 28
Percentage of participantsAbataceptPlacebo
Percentage of Participants on Invasive Mechanical Ventilation or Died Prior to or on Day 2830.0 (15.8 to 44.2)31.6 (10.7 to 52.5)
Statistical analysis
  • Abatacept vs Placebo · Cochran-Mantel-Haenszel Chi-Square test · p = 0.9297 · Odds ratio (or): 1.07 · 95% CI 0.26 to 4.49
SecondaryAdjusted Mean Change From Baseline in the Ordinal 8-Point Clinical Status Scale on Day 28

Adjusted mean change from baseline based on the following Ordinal 8-point Clinical Status Scale that was proposed for the National Institute of Allergy and Infectious Diseases (NIAID) Adaptive COVID-19 Treatment Trial (ACTT) and is recorded by the worst score (lowest number) state for each day: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, on non-invasive mechanical ventilation or high-flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized, limitation on activities and/or requiring home oxygen; 8. Not hospitalized, no limitation on activities Baseline is defined as the last assessment done prior or on Day 1

Time frame:
Baseline and on Day 28
Reported as:
Mean · Score on a scale
Adjusted Mean Change From Baseline in the Ordinal 8-Point Clinical Status Scale on Day 28
Score on a scaleAbataceptPlacebo
Adjusted Mean Change From Baseline in the Ordinal 8-Point Clinical Status Scale on Day 283.20 ± 0.3952.56 ± 0.528
Statistical analysis
  • Abatacept vs Placebo · Cochran-Mantel-Haenszel · p = 0.7400 · Adjusted mean difference from placebo: 0.64 · 95% CI -0.55 to 1.82
SecondaryPercentage of Participants Who Died

Percentage of participants who died due to any cause. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 1) Death

Time frame:
From first dose to 28 days post first dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Died
Percentage of participantsAbataceptPlacebo
Percentage of Participants Who Died12.5 (2.3 to 22.7)15.8 (0.0 to 32.2)
Statistical analysis
  • Abatacept vs Placebo · Cochran-Mantel-Haenszel Chi-Square test · p = 0.9684 · Estimate of difference: -0.10 · 95% CI -20.55 to 20.34Estimate of Difference is based on minimum risk weights
SecondaryPercentage of Participants Alive and Free of Respiratory Failure on Day 28±3

Respiratory failure is defined by the type of resources required as defined by the use of any of these: Mechanical ventilation, extracorporeal membrane oxygenation (ECMO) or oxygen delivery by noninvasive positive pressure or high flow nasal cannula. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitation on activities

Time frame:
Day 28±3
Reported as:
Number · Percentage of participants
Percentage of Participants Alive and Free of Respiratory Failure on Day 28±3
Percentage of participantsAbataceptPlacebo
Percentage of Participants Alive and Free of Respiratory Failure on Day 28±375.0 (61.6 to 88.4)73.7 (53.9 to 93.5)
Statistical analysis
  • Abatacept vs Placebo · Cochran-Mantel-Haenszel · p = 0.8504 · Odds ratio (or): 0.85 · 95% CI 0.18 to 3.97
SecondaryPercentage of Participants Returned to Room Air on Day 28

Recovery of pulmonary function is assessed by the percentage of participants returned to room air on day 28 after they were oxygen dependent and dependence on oxygen has been noted to be prolonged even after hospital discharge. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 8) Not hospitalized, no limitation on activities

Time frame:
Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants Returned to Room Air on Day 28
Percentage of participantsAbataceptPlacebo
Percentage of Participants Returned to Room Air on Day 2870.0 (55.8 to 84.2)57.9 (35.7 to 80.1)
Statistical analysis
  • Abatacept vs Placebo · Cochran-Mantel-Haenszel · p = 0.2724 · Odds ratio (or): 2.29 · 95% CI 0.53 to 9.82
  • Abatacept vs Placebo · Estimate of difference: 12.78 · 95% CI -10.61 to 36.17
SecondaryPercentage of Participants Alive and Discharged From the Hospital by Day 28

Percentage of participants alive and discharged from the hospital on day 28. Participants in the following Ordinal 8-point Clinical Status Scale that is recorded by the worst score (lowest number) state for each day meet this definition: 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitation on activities

Time frame:
From day 1 up to day 28
Reported as:
Number · Percentage of participants
Percentage of Participants Alive and Discharged From the Hospital by Day 28
Percentage of participantsAbataceptPlacebo
Percentage of Participants Alive and Discharged From the Hospital by Day 2882.5 (70.7 to 94.3)73.7 (53.9 to 93.5)
Statistical analysis
  • Abatacept vs Placebo · Cochran-Mantel-Haenszel · p = 0.4734 · Odds ratio (or): 2.03 · 95% CI 0.33 to 12.64
  • Abatacept vs Placebo · Estimate of difference: 5.43 · 95% CI -16.71 to 27.57Estimate of difference is based on minimum risk weights
SecondaryPercentage of Participants With Serious Adverse Events

Percentage of participants with serious adverse events (SAEs). SAE is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life threatening * Requires inpatient hospitalization * Results in persistent or significant disability * Is a congenital anomaly/birth defect * Is an important medical event

Time frame:
From first dose to 60 days post first dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events
Percentage of participantsAbataceptPlacebo
Percentage of Participants With Serious Adverse Events20.031.6
SecondaryPercentage of Participants With Serious Adverse Events (SAEs) of the Infections and Infestations System Organ Class

Percentage of participants with Serious Adverse Events (SAEs) of the infections and infestations System Organ Class (SOC)

Time frame:
From first dose to 60 days post first dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) of the Infections and Infestations System Organ Class
Percentage of participantsAbataceptPlacebo
Percentage of Participants With Serious Adverse Events (SAEs) of the Infections and Infestations System Organ Class7.55.3

Adverse events

Collected over Adverse Events and Serious Adverse Events were monitored from first dose to 60 days post last dose (Up to approximately 2 months). Participants were assessed for All Cause Mortality from their date of randomization until the study was completed (up to approximately 11 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept7/42 (16.7%)8/40 (20%)8/40 (20%)
Placebo5/19 (26.3%)6/19 (31.6%)10/19 (52.6%)
Most frequent serious events
Most frequent serious events
EventAbataceptPlacebo
HypoxiaRespiratory, thoracic and mediastinal disorders4/404/19
Cardiac arrestCardiac disorders3/402/19
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/402/19
Multiple organ dysfunction syndromeGeneral disorders0/401/19
SepsisInfections and infestations2/401/19
Acute kidney injuryRenal and urinary disorders0/401/19
PneumothoraxRespiratory, thoracic and mediastinal disorders1/401/19
Pneumonia klebsiellaInfections and infestations1/400/19
Pseudomonal sepsisInfections and infestations1/400/19
SeizureNervous system disorders1/400/19
Most frequent other events
Showing 10 of 32
Most frequent other events
EventAbataceptPlacebo
AnaemiaBlood and lymphatic system disorders2/402/19
Oedema peripheralGeneral disorders1/402/19
PyrexiaGeneral disorders3/402/19
HypertensionVascular disorders2/402/19
HypotensionVascular disorders0/402/19
Atrial fibrillationCardiac disorders2/401/19
Mastoid effusionEar and labyrinth disorders0/401/19
Eye haemorrhageEye disorders0/401/19
Catheter site haemorrhageGeneral disorders0/401/19
FatigueGeneral disorders0/401/19

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AbataceptPlaceboTotal
Mean61.1 ± 14.2060.7 ± 14.4861.0 ± 14.17
Sex: Female, Male
Sex: Female, Male(Participants)AbataceptPlaceboTotal
Female13619
Male291342
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AbataceptPlaceboTotal
Hispanic or Latino23932
Not Hispanic or Latino191029
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AbataceptPlaceboTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander011
Black or African American437
White281038
More than one race000
Unknown or Not Reported9413
08

Study locations

10 sites
  • Alternative Research Associates, Llc
    Hialeah, Florida 33012, United States
  • Alternative Research Associates
    Hialeah, Florida 33012, United States
  • Norton Infectious Disease Institute
    Louisville, Kentucky 40202, United States
  • Boston Childrens Hospital
    Boston, Massachusetts 02115, United States
  • Local Institution - 0002
    Boston, Massachusetts 02215, United States
  • Atlantic Health System
    Morristown, New Jersey 07960, United States
  • Methodist Health System Clinical Research Institute (MHSCRI)
    Dallas, Texas 75203, United States
  • CardioPulmonary Research
    Guaynabo, 00968, Puerto Rico
  • Ponce Medical School Foundation
    Ponce, 00780, Puerto Rico
  • Fundacion de Investigacion de Diego
    San Juan, 00927, Puerto Rico
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Aug 2021, 9 months.

Results were first posted in Oct 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2020
First posted
Jul 15, 2020
StartActual
Oct 14, 2020
Primary completionActual
Aug 12, 2021
CompletionActual
Sep 13, 2021
Results first posted
Oct 7, 2022
Last update
Oct 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04472494
Responsible party
Sponsor
First posted
Jul 15, 2020
Start date
Oct 14, 2020
Primary completion
Aug 12, 2021
Completion
Sep 13, 2021
Results posted
Oct 7, 2022
Last update
Oct 7, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion